论文部分内容阅读
第二代CA125(CA125 Ⅱ)放免测定使用一种新的CA125捕获抗体即M-11,一种鼠的单克隆抗体,它由CA125多个亚种免疫沉淀产生。本文对①大量妇科病人;②不同的病人群体;③不同良性妇科病人的CA125和CA125 Ⅱ进行比较。 自愿参加本研究887例中822例18岁以上者为研究对象,有完整的问答表并确定最后诊断。其中31例门诊随访孕妇,154例为口服避孕药(雌和/或孕激素),99例已绝经,82例确诊不排卵(已停经35～90天),其余456例为绝经前月经周期正常的妇女,其中42例在周期1～5天,414例在卵泡期及黄
The second generation of CA125 (CA125 II) radioimmunoassay uses a novel CA125 capture antibody, M-11, a murine monoclonal antibody produced by immunoprecipitation of several CA125 subspecies. This article ① a large number of gynecological patients; ② different patient groups; ③ different benign gynecological patients with CA125 and CA125 Ⅱ were compared. Of 887 patients who volunteered to participate in the study, 822 were over 18 years of age as subjects, with a complete questionnaire and final diagnosis. Among them, 31 outpatients were followed up with pregnant women, 154 were oral contraceptives (estrogen and / or progestin), 99 were postmenopausal, 82 were diagnosed as not ovulating (35 to 90 days after menopause), and the remaining 456 were normal menopausal menstrual cycles Of the women, of which 42 cases in the cycle of 1 to 5 days, 414 cases in the follicular phase and yellow